In a sign that hopes for quick medical benefits from stem cells are fading, ES Cell International (ESI)—a company established with fanfare in Singapore 7 years ago—is halting work on human embryonic stem (hES) cell therapies. Investors lost interest because “the likelihood of having products in the clinic in the short term was vanishingly small,” says Alan Colman, a stem cell pioneer who until last month was ESI's chief executive.
No takes yet. Share an insight, caveat, or question.
Dennis Normile (2007) studied this question.